Pan-Malaria Transmission-Blocking Vaccine AnAPN1

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

January 22, 2025

Study Completion Date

January 31, 2025

Conditions
Malaria
Interventions
DRUG

Vaccine AnAPN1

AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM\_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.

Trial Locations (1)

1437

Centre de Recherches Médicales de Lammbaréné, Lambaréné

All Listed Sponsors
collaborator

Global Health Innovative Technology Fund

OTHER

lead

Centre de Recherche Médicale de Lambaréné

OTHER